CD22-directed Immunoconjugate [EPC]

2992 reported adverse events

Drugs of this class: INOTUZUMAB OZOGAMICIN

These side effects are most commonly reported by patients taking drugs of the CD22-directed Immunoconjugate [EPC] class:

# Side effect Count
0 DEATH 360
1 FEBRILE NEUTROPENIA 267
2 VENOOCCLUSIVE LIVER DISEASE 260
3 OFF LABEL USE 232
4 PYREXIA 198
5 NEOPLASM PROGRESSION 155
6 THROMBOCYTOPENIA 154
7 ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT 148
8 DRUG INEFFECTIVE 143
9 CYTOKINE RELEASE SYNDROME 142
See all common reactions for CD22-directed Immunoconjugate [EPC]

Drugs of the CD22-directed Immunoconjugate [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 LINEAGE SWITCH LEUKAEMIA 9 0.1698
1 COSTAL CARTILAGE FRACTURE 5 0.1471
2 HAEMOPHILUS BACTERAEMIA 6 0.1224
3 PURTSCHER RETINOPATHY 7 0.0854
4 LEUKAEMIC INFILTRATION EXTRAMEDULLARY 19 0.0745
5 B PRECURSOR TYPE ACUTE LEUKAEMIA 27 0.0696
6 BONE MARROW LEUKAEMIC CELL INFILTRATION 5 0.0610
7 ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT 148 0.0573
8 VENOOCCLUSIVE DISEASE 132 0.0527
9 VENOOCCLUSIVE LIVER DISEASE 260 0.0526
See all enriched reactions for CD22-directed Immunoconjugate [EPC]